| Followers | 928 |
| Posts | 48536 |
| Boards Moderated | 0 |
| Alias Born | 07/22/2008 |
Thursday, May 09, 2024 7:56:10 PM
I guess these "FREE SHARES" have to be digested along with any additional "SHORT SHARES" from 9.55 down all the way to 1.91... From the 10-Q. 6.9 million shares for 69 bucks.
7M shares x avg sell price of $8 = $56 million...
Did these shorts cover? Yet?
Nowhere to go but UP? This could bottom and pOp...JMO...have to see if that 17¢ EPS was a one-time-event...revenue doubled...
$CTMX
As of May 6, 2024, the registrant had 77,919,369 shares of common stock, $0.00001 par value per share, outstanding. This number does not include 6,923,077 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of May 6, 2024 (which are immediately exercisable at an exercise price of $0.00001 per share of common stock, subject to beneficial ownership limitations) sold in the registrant’s private placement in July 2023.
7M shares x avg sell price of $8 = $56 million...
Did these shorts cover? Yet?
Nowhere to go but UP? This could bottom and pOp...JMO...have to see if that 17¢ EPS was a one-time-event...revenue doubled...
$CTMX
Recent CTMX News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/20/2026 08:15:43 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/16/2026 08:10:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 10:41:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 10:35:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 10:25:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 10:21:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:05:37 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/18/2026 08:05:53 PM
- CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 03/18/2026 02:46:40 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/16/2026 08:37:02 PM
- CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 03/16/2026 08:04:55 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 03/16/2026 08:01:39 PM
- CytomX highlights clinical progress for lead cancer drug in Q4 update • IH Market News • 03/16/2026 03:36:20 PM
- CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/16/2026 11:05:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 11:04:08 AM
- CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer • GlobeNewswire Inc. • 03/16/2026 11:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 03/04/2026 08:18:13 PM
- CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 • GlobeNewswire Inc. • 03/04/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:28:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:27:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:23:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:22:15 PM
- CytomX Therapeutics to Present at Upcoming February Conferences • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development • GlobeNewswire Inc. • 01/27/2026 12:00:00 PM

